StockData
EoCene Ltd. logo

EoCene Ltd. (EOCN) stock

EOCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 31, 2026Score 5/30
$2.46−0.07 (-2.77%)

Close on Nov 17, 2026Market cap $2.46MP/E –Yield –

EoCene r&d expenses

Research and development expenses are spending on new products and technology.

EoCene's R&D Expenses for the twelve months ending Dec 31, 2025 was $4.87M, up 63.6% year over year. For fiscal 2025 it was $4.87M, up 63.6% from the year before. Over ten years it grew -4.4% a year on average. The highest annual figure on record is $27.22M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.87M+63.6%
FY2024Dec 31, 2024$2.98M-16.5%
FY2023Dec 31, 2023$3.57M-72.5%
FY2022Dec 31, 2022$13.00M-52.3%
FY2021Dec 31, 2021$27.22M+4.4%
FY2020Dec 31, 2020$26.08M+43.5%
FY2019Dec 31, 2019$18.18M+118.7%
FY2018Dec 31, 2018$8.31M-13.9%
FY2017Dec 31, 2017$9.65M-32.4%
FY2016Dec 31, 2016$14.27M+87.1%
FY2015Dec 31, 2015$7.63M+14.5%
FY2014Dec 31, 2014$6.66M-7.5%
FY2013Dec 31, 2013$7.21M+195.0%
FY2012Dec 31, 2012$2.44M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.78M+66.2%
Q4 FY2025Dec 31, 2025$2.10M+184.0%
Q3 FY2025Sep 30, 2025$1.09M+103.4%
Q2 FY2025Jun 30, 2025$1.06M+30.8%
Q4 FY2024Dec 31, 2024$1.07M-58.4%
Q3 FY2024Sep 30, 2024$738.00K-89.5%
Q2 FY2024Jun 30, 2024$534.00K-89.3%
Q2 FY2023Jun 30, 2023$809.00K-76.8%
Q2 FY2022Jun 30, 2022$2.58M+33.0%
Q2 FY2021Jun 30, 2021$7.04M+199.8%
Q2 FY2020Jun 30, 2020$4.97M+47.9%
Q2 FY2019Jun 30, 2019$3.49M+123.7%
Q2 FY2018Jun 30, 2018$1.94M–
Q2 FY2017Jun 30, 2017$2.35M–
Q2 FY2016Jun 30, 2016$3.36M–
Q2 FY2015Jun 30, 2015$1.56M–

More EoCene figures

See a number that looks wrong?